A new research has shown that a genetically modified version of the herpesvirus may be effective in treating difficult-to-eradicate cancer tumors, with one patient having experienced a complete remission for 15 months so far.shows that although preliminary data from a Phase I trial is promising, more research will be needed to confirm the treatment’s early success.
“Our study shows that a genetically engineered, cancer-killing virus can deliver a one-two punch against tumors—directly destroying cancer cells from within while also calling in the immune system against them,” the lead author Kevin Harrington, professor of Biological Cancer Therapies at The Institute of Cancer Research , said in a statement.The RP2 treatment, developed by the company Replimune, is designed to work on two fronts.
In a Phase I trial conducted by scientists at ICC and Royal Marsden NHS Foundation Trust in the UK, RP2 was said to have been given as the only treatment to nine patients with advanced cancers that failed to respond to other therapies; it was also given in combination with another immunotherapy drug to 30 patients.
There were no life-threatening adverse events reported in the trial, with the most common symptoms post-treatment being fever, chills, and other flu-like illnesses.have been hopeful about cancer-fighting viruses for a long time, it’s only recently that this hope has finally started to pay off.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: DailyPostNGR - 🏆 11. / 59 Read more »